Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc.

NAUT·NASDAQ

$2.58

-3.7%
HealthcareBiotechnology

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

At a Glance

Live Snapshot
Market Cap$327.86M
EPS-0.4700
P/E Ratio-5.49
Earnings Date08/04/2026

naut

Gross Profit

Last Annual Value

-6.46M

3-Year CAGR

-24%

5-Year CAGR

-22%

10-Year CAGR

%

Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Competitors Analysis of Gross Profit

NAUT · NASDAQ
CompanyGross Profit
CAGR 3Y
CAGR 5Y
CAGR 10Y
-6.46M
N/AN/AN/A 
-8.44M
N/AN/AN/A
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
-49.00K
N/AN/AN/A
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
-15.01M
N/AN/AN/A
64.20M
-25.9%39.0%12.3%
0.00
N/AN/AN/A
-698.89K
N/AN/AN/A
AGEN logo
Agenus Inc.
NASDAQ:AGEN
103.17M
N/A-1.9%N/A
-228.00K
N/AN/AN/A
-124.66K
N/AN/AN/A
0.00
N/AN/AN/A
Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Fair Value Envelope

NAUT · NASDAQ

Our analysis suggests that NAUT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.58, this represents a potential HIDDEN relative to our calculated worth for Nautilus Biotechnology, Inc..

Intrinsic Value
Current Price: $2.58